Form 4: Caribou Biosciences Director Granted Stock Options
Insider Stock Option Grant
Caribou Biosciences Director David Lee Johnson was granted 45,000 stock options with an exercise price of $1.80, vesting monthly over one year.
Summary
- David Lee Johnson, a Director of Caribou Biosciences, Inc. (CRBU), was granted options to purchase 45,000 shares of common stock.
- The transaction date for this grant was February 20, 2026.
- The exercise price for these options is $1.80 per share.
- The options will vest at a rate of one-twelfth of the shares on each monthly anniversary of the grant date.
- Full vesting of the options is expected by February 20, 2027, contingent on Mr. Johnson's continued service to the Issuer.
- The options have an expiration date of February 19, 2036.
- The transaction was made pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive signal, indicating continued director engagement and a structured approach to equity compensation through a Rule 10b5-1 plan.
Positives
- The grant of stock options to a director aligns management's long-term interests with those of shareholders.
- The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged and structured approach to equity compensation.
Future Outlook
The vesting schedule indicates an expectation for David Lee Johnson to continue providing service to Caribou Biosciences, Inc. through February 20, 2027.
Industry Context
StockSavvy.ai notes that insider option grants, especially when structured under a Rule 10b5-1 plan, can signal management's long-term commitment and confidence in the company's future performance, aligning their interests with shareholders.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation Plan | The option grant was made pursuant to a Rule 10b5-1(c) plan, which is a pre-arranged trading plan designed to satisfy affirmative defense conditions against insider trading. | 02/20/2026 | Enhances transparency and reduces the risk of insider trading allegations by establishing a pre-determined schedule for equity transactions. |
Stakeholder Impact
- Shareholders may view the director's increased equity stake as a positive alignment of interests, potentially fostering greater confidence in management's long-term commitment to the company's success.
Next Steps
- Continued monthly vesting of the granted options until full vesting on February 20, 2027, contingent on continued service.
Key Dates
| Date | Description |
|---|---|
| 02/20/2026 | Grant date of the options to purchase common stock. |
| 02/20/2027 | Date by which the options will be fully vested, subject to continued service. |
| 02/19/2036 | Expiration date of the granted options. |
Keywords
Caribou Biosciences, CRBU, stock options, insider transaction, Form 4, director, equity compensation, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.